WHAT HAPPENED TO EYLEA EXPANSION POSITIONS?

Quote

anonymous

Guest
I had posted for an Eylea expansion role. It appeared that I was moving forward, at least to the review stage. I had been an MS with Praluent. Trying to figure out if I am now listed as "withdrawn" because the role was withdrawn, or I was eliminated by having been part of the Praluent team?? Anyone have any info on these roles?
 






anonymous said:
I had posted for an Eylea expansion role. It appeared that I was moving forward, at least to the review stage. I had been an MS with Praluent. Trying to figure out if I am now listed as "withdrawn" because the role was withdrawn, or I was eliminated by having been part of the Praluent team?? Anyone have any info on these roles?
Click to expand...


All openings were filled
 






anonymous said:
I had posted for an Eylea expansion role. It appeared that I was moving forward, at least to the review stage. I had been an MS with Praluent. Trying to figure out if I am now listed as "withdrawn" because the role was withdrawn, or I was eliminated by having been part of the Praluent team?? Anyone have any info on these roles?
Click to expand...
It’s the ladder. They don’t won’t any ole Praluent reps. Total elimination, totally.
 






That's totally NOT true. They took a Praluent rep into the Eylea sales group in Florida. And seriously, after you have been through the fire with Praluent, why would you want to pay back your severance just to stay with Regeneron? There are tons of jobs out there right now.
 


















anonymous said:
I would go back to Regeneron in a second!! I love the culture. We were laid off because of business, not because of anything we did wrong.
Click to expand...

Regeneron management was never 100% committed to Praluent when things got tough. Len was totally arrogant to think managed care companies would grab their ankles and take that price. Managed care stepped in and created the most difficult prior auth process and denial rate of any drug in last 10 years. The first year of launch 18% of scripts were approved and on average each one took extensive office staff time and each one was denied on average at least twice . There was never a problem with reps getting scripts. We had more scripts we knew what to do with but Lens HUB with 9 people working in day 1 to handle 320 reps from Sanofi and Regeneron made them behind 3 weeks 4 hours into the first day the HUB was operational..Anyone remember that Catwoman at Sanofi screeching at us that the Hub was waiting for our customers to call. PA's had to be faxed in (nothing electronic)- amazing in today's world and little things like fax line busy, or nobody keeping up putting paper in fax machines . We literally had 100's of scripts just disappear. Or the ridiculous contest they setup at launch just based on volume of scripts. Reps had offices send scripts in based on that they smoked or they were 10lbs overweight which further slowed process down but we rewarded reps with trips and accolades. Let's not forget about the cracker jack Sanofi PC team that got credit for every midlevel script (PA's and NP's) and some specialists. They were rewarded with bonuses and trips also for doing nothing. This was a complete mess. Len became less engaged and although Regeneron had done some shady patent dealings Len spent a fortune legally fighting Amgens claims for 3 years to only throw in the towel when Praluent finally started to win back share from Amgen after Praluent lost share during patent. Praluent reps were disregarded like trash in layoffs. A few escaped to Dupixent but the failure of Praluent falls squarely on Len.
 






anonymous said:
Regeneron management was never 100% committed to Praluent when things got tough. Len was totally arrogant to think managed care companies would grab their ankles and take that price. Managed care stepped in and created the most difficult prior auth process and denial rate of any drug in last 10 years. The first year of launch 18% of scripts were approved and on average each one took extensive office staff time and each one was denied on average at least twice . There was never a problem with reps getting scripts. We had more scripts we knew what to do with but Lens HUB with 9 people working in day 1 to handle 320 reps from Sanofi and Regeneron made them behind 3 weeks 4 hours into the first day the HUB was operational..Anyone remember that Catwoman at Sanofi screeching at us that the Hub was waiting for our customers to call. PA's had to be faxed in (nothing electronic)- amazing in today's world and little things like fax line busy, or nobody keeping up putting paper in fax machines . We literally had 100's of scripts just disappear. Or the ridiculous contest they setup at launch just based on volume of scripts. Reps had offices send scripts in based on that they smoked or they were 10lbs overweight which further slowed process down but we rewarded reps with trips and accolades. Let's not forget about the cracker jack Sanofi PC team that got credit for every midlevel script (PA's and NP's) and some specialists. They were rewarded with bonuses and trips also for doing nothing. This was a complete mess. Len became less engaged and although Regeneron had done some shady patent dealings Len spent a fortune legally fighting Amgens claims for 3 years to only throw in the towel when Praluent finally started to win back share from Amgen after Praluent lost share during patent. Praluent reps were disregarded like trash in layoffs. A few escaped to Dupixent but the failure of Praluent falls squarely on Len.
Click to expand...
payers do not care about the price, they care about the rebate. they never pay full wac. the number one selling drug in history is around $65k/year versus praluent's former $15k/year
 






anonymous said:
payers do not care about the price, they care about the rebate. they never pay full wac. the number one selling drug in history is around $65k/year versus praluent's former $15k/year
Click to expand...

65k a year for medicine in biologic would be in rare disease. Praluent at 15k a year in LDL market would far exceed what the 65k price tag on the rare disease drug and wouldn't come close to the billions potential in LDL market. Look what Lipitor did at 350.00 per month (billions).Payers do care about price. Yes in rebates but your talking about two completely different markets and volume potential. Payers have ability to put up barriers in approvals like they did in full force despite 50-60% ldl reductions. If Len had been smart and not greedy and priced it where it was eventually dropped to at $5400.00 per year we wouldn't be having this conversation about how Len made Praluent reps walk the plank after 4 years of misery. The reps on the frontline knew immediately at meeting when they released price this would be a problem along with the 12 page Prior Auth form the Hub produced. Brilliant marketing and execution!!!!!
 


















anonymous said:
65k a year for medicine in biologic would be in rare disease. Praluent at 15k a year in LDL market would far exceed what the 65k price tag on the rare disease drug and wouldn't come close to the billions potential in LDL market. Look what Lipitor did at 350.00 per month (billions).Payers do care about price. Yes in rebates but your talking about two completely different markets and volume potential. Payers have ability to put up barriers in approvals like they did in full force despite 50-60% ldl reductions. If Len had been smart and not greedy and priced it where it was eventually dropped to at $5400.00 per year we wouldn't be having this conversation about how Len made Praluent reps walk the plank after 4 years of misery. The reps on the frontline knew immediately at meeting when they released price this would be a problem along with the 12 page Prior Auth form the Hub produced. Brilliant marketing and execution!!!!!
Click to expand...
 






anonymous said:
65k a year for medicine in biologic would be in rare disease. Praluent at 15k a year in LDL market would far exceed what the 65k price tag on the rare disease drug and wouldn't come close to the billions potential in LDL market. Look what Lipitor did at 350.00 per month (billions).Payers do care about price. Yes in rebates but your talking about two completely different markets and volume potential. Payers have ability to put up barriers in approvals like they did in full force despite 50-60% ldl reductions. If Len had been smart and not greedy and priced it where it was eventually dropped to at $5400.00 per year we wouldn't be having this conversation about how Len made Praluent reps walk the plank after 4 years of misery. The reps on the frontline knew immediately at meeting when they released price this would be a problem along with the 12 page Prior Auth form the Hub produced. Brilliant marketing and execution!!!!!
Click to expand...
 






anonymous said:
65k a year for medicine in biologic would be in rare disease. Praluent at 15k a year in LDL market would far exceed what the 65k price tag on the rare disease drug and wouldn't come close to the billions potential in LDL market. Look what Lipitor did at 350.00 per month (billions).Payers do care about price. Yes in rebates but your talking about two completely different markets and volume potential. Payers have ability to put up barriers in approvals like they did in full force despite 50-60% ldl reductions. If Len had been smart and not greedy and priced it where it was eventually dropped to at $5400.00 per year we wouldn't be having this conversation about how Len made Praluent reps walk the plank after 4 years of misery. The reps on the frontline knew immediately at meeting when they released price this would be a problem along with the 12 page Prior Auth form the Hub produced. Brilliant marketing and execution!!!!!
Click to expand...

Nailed it!
 












Top Bottom
Back
Quote